Craig A. Portell, MD, previews his session on sequencing therapies in relapsed/refractory mantle cell lymphoma being presented at the 2024 Society of Hematologic Oncology Annual Meeting.
Craig A. Portell, MD, associate professor of medicine at University of Virginia, previews his session on sequencing therapies in relapsed/refractory mantle cell lymphoma being presented at the 2024 Society of Hematologic Oncology (SOHO) Annual Meeting.
According to Portell, as more is learned about Bruton’s tyrosine kinase (BTK) inhibitor resistance, it can be a challenge to know what to do afterwards. He adds that the chimeric antigen receptor (CAR) T-cell therapy space has been very helpful with this.
He also remains hopeful that more data on bispecific antibodies, covalent BTK inhibitors, venetoclax (Venclexta), etc., all of which are hard to know how to sequence, will continue to help address challenges in the field of relapsed/refractory mantle cell lymphoma.
Further, Portell offers some insights on what one can expect from this session at SOHO, as well as additional sessions that are of particular interest to him and colleagues.
Transcription:
0:09 | So, today I am going to be talking about sequencing therapies in relapsed mantle cell lymphoma. [We are] starting first with patients, whether they have been exposed to BTK inhibitors or not, and how that may impact the decision making, and then, after exposure to BTK inhibitors, how to fit CAR T-cell therapy in vs a non covalent BTK inhibitor, and [we will] talk about some special scenarios, particularly with p53-mutated relapse disease.
0:39 | [We will be] really going through the pathways of when a patient would relapse in various different scenarios. So, hopefully that will be informative and give some suggestions about how to manage patients in certain scenarios after progression with various different disease characteristics.
0:59 | [Overall], the lymphoma sessions, I think, in general, are going to be very well reviewed and thoughtful. So, I am looking forward to hearing what my colleagues have to say.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More